This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Acorda Therapeutics Reports Third Quarter 2013 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter ended September 30, 2013.

“We are pleased with the continued growth and progress of the Company. AMPYRA net sales for the third quarter were in line with our expectations and we are encouraged by fourth quarter sales to date. We also have a strong cash position of approximately $350 million. The strength of the AMPYRA franchise and our balance sheet is enabling us to invest in our pipeline of promising clinical-stage compounds, which have attained a number of important milestones in 2013,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Pending agreement with FDA, we anticipate beginning a Phase 2b/3 study of a once-daily formulation of dalfampridine in post-stroke walking deficits in the second quarter of 2014. In addition, our Diazepam Nasal Spray NDA filing is on track for this year. Acorda now has six innovative products in clinical development, positioning us well for future growth.”

FINANCIAL RESULTS

The Company reported GAAP net income of $7.5 million for the quarter ended September 30, 2013, or $0.18 per diluted share, including share-based compensation charges totaling $6.5 million. GAAP net income in the same quarter of 2012 was $9.6 million, or $0.24 per diluted share, including share-based compensation charges totaling $5.6 million.

Non-GAAP net income for the quarter ended September 30, 2013 was $15.0 million, or $0.36 per diluted share. Non-GAAP net income in the same quarter of 2012 was $15.2 million, or $0.38 per diluted share.

AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg net revenue - For the quarter ended September 30, 2013, the Company reported AMPYRA net revenue of $77.8 million, compared to $69.8 million in net revenue for the same quarter in 2012. Through the first three quarters of 2013, net sales increased 13% over the same period in 2012.

The Company narrowed 2013 AMPYRA net revenue guidance to $295-$305 million, from $285-$315 million.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,192.97 -21.45 -0.12%
S&P 500 2,110.75 +0.01 0.00%
NASDAQ 4,981.86 -6.03 -0.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs